The U.S. Food and Drug Administration has rolled out new agentic AI capabilities across the agency, enabling staff to leverage advanced, goal-driven AI systems to assist with complex, multi-step regulatory tasks. For the Center for Tobacco Products (CTP), these tools are expected to enhance efficiency and consistency in key functions such as premarket tobacco product application (PMTA) reviews, substantial equivalence (SE) assessments, scientific evaluations, and administrative processes. The deployment builds on the success of the agency’s earlier LLM tool, Elsa, and is part of a broader initiative to modernize FDA operations.

These agentic AI tools will also support post-market surveillance, inspections, and compliance activities related to tobacco products, contributing to more robust oversight and improved regulatory outcomes. Built within a secure GovCloud environment, the system does not train on input data or confidential information submitted by regulated industry, safeguarding sensitive tobacco-product data. The FDA’s latest AI initiative underscores its commitment to strengthening science-based regulation and ensuring the protection of public health.

Consumer News Region
Consumer News Tags
United Staes of America (USA); Agentic AI; Post-market surveillance; Inspections